Your session is about to expire
← Back to Search
BBP-398 + Nivolumab for Lung Cancer
Study Summary
This trial is testing a new cancer drug, BBP-398, to see if it is safe and effective when used with another cancer drug, nivolumab.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer worsened within 4 months of starting treatment with an anti-PD-(L)1 drug.My advanced lung cancer has a KRAS mutation, confirmed within the last year.My cancer has worsened after treatment including platinum chemotherapy and anti-PD-(L)1 therapy.My cancer got worse or came back within 3 months after stopping immunotherapy.I have not received a live vaccine in the last 30 days.I have not had extensive radiation therapy within the last month.I haven't taken high-dose steroids or other immune-weakening drugs in the last 2 weeks.I am fully active or restricted in physically strenuous activity but can do light work.My organs are functioning well.You have a known or suspected autoimmune disease.Patients must have a way to measure their disease according to specific guidelines.I have had a bone marrow transplant from a donor.I have tumors or cancer spread to my brain.
- Group 1: Dose Escalation Level 1
- Group 2: Dose Escalation Level 2
- Group 3: Dose Escalation Level 3
- Group 4: Dose Expansion
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the upper bound of participants for this investigation?
"Affirmative. Clinicaltrials.gov hosts evidence that this clinical trial, posted on May 1st 2022 and recently updated in mid-May, is currently recruiting patients with a target of 45 enrollees from one site."
Are there still available slots for individuals to join this trial?
"Correct. According to information available on clinicaltrials.gov, this medical research was first posted on May 1st 2022 and is still actively enrolling patients. The trial requires 45 people at a single site."
What have been the observed effects of combining BBP-398 and nivolumab in clinical trials?
"Due to this being an early stage trial, the safety of BBP-398 with nivolumab has been estimated at 1 on a scale of one to three. This is because there are scant data regarding its efficacy and security profile."
Share this study with friends
Copy Link
Messenger